money received from the IPO after deducting the actual expenses 4. Acquisition of all ordinary shares of Modern Pharma Company Limited, "Modern Company", which is a transaction concerning asset
issuer has been in operation), in the same currency as the financial statements provided in response to Part VIII. Financial Information. If interim period financial statements are included, the selected
be presented for the three most recent financial years (or such shorter period that the issuer has been in operation), in the same currency as the financial statements provided in response to Part VIII
1,359 MB increased from 9M/2016 which was at 885 MB. However, the company’s performance was still impacted from Stock Loss and appreciating Baht currency which resulted in the reported net profit in
pay1 provision in 2Q19 and employee remuneration in 4Q19. Net FX gain was Bt308mn, increasing from Bt119mn in FY18, which was mostly unrealized gain from fluctuated currency whereas foreign debts were
by depreciation of Thai Baht. Gain on foreign currency exchange was mainly associated with the USD loan related to the SGAH transaction and was non-cash in nature. Net profit (loss) attributable to
- commissioning activities planned in December 2017 and startup early 2018. In addition to improved cash flows as a result of the better performance, the Company’s Balance Sheet al- so strengthened as a consequence
]) Factsheet Type of structure notes: long-term structured notes Tenor: short-term structured notes Issue date: Currency: Maturity date: Credit rating:1 None Guarantor/Aval Issue Issuer Rated by on
Resources CONTENTS Executive Summary and Management Guidelines to Mitigate the Effects of the COVID-19 Outbreak 03 Statement of Income 09 Business Performance 11 Statement of Financial Position 24 Cash of
% calculation is based on THB currency 16 Table 10: IVL Consolidated Statement of Financial Position THB in mill ions 30-Jun-17 31-Dec-16 31-Jun-17 vs. 31-Dec-16 Assets Cash and current investments 5,256 4,140 27